News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News 📰

Chronic Pain Market Size, Share Analysis, Growth Trends and Forecast 2025-2033

Chronic Pain Market is segmented By Type (Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post-Operative Pain, Migraine, Others), By Treatment Type (Drug Class, Devices), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published: May 2025 || SKU: PH8948
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
Get Free Sample

Get Expert Insights on Chronic Pain Market

Talk to a

Chronic Pain Market – Industry Trends & Overview

Chronic Pain Market reached US$ 79.96 Billion in 2024 and is expected to reach US$ 142.28 Billion by 2033, growing at a CAGR of 7.5 % during the forecast period 2025-2033.

The global chronic pain market refers to the industry focused on diagnosing, treating, and managing chronic pain, defined as pain persisting for more than three months, often arising from conditions such as injuries, surgeries, arthritis, diabetes, cancer, and nerve damage. Chronic pain can significantly impair quality of life and daily functioning, affecting hundreds of millions worldwide.

Key drivers of market growth include the rising prevalence of chronic diseases, an aging population more susceptible to pain conditions, and increased awareness and diagnosis of chronic pain. Additionally, innovation in pain therapeutics and devices, such as neurostimulation systems and minimally invasive treatments, is expanding treatment options and driving market expansion.

Opportunities in the chronic pain market are emerging from ongoing research into novel drugs and alternative therapies, including non-opioid medications, neural stimulation, gene therapies, and precision diagnostics. The development of portable, user-friendly pain management devices and the integration of digital health solutions such as telemedicine and wearable technology present significant growth avenues. 

Current trends shaping the industry include a shift toward non-opioid pain management due to concerns over addiction and side effects, the adoption of holistic and multidisciplinary approaches, and the integration of wearable devices and digital health platforms for remote monitoring and care. 

Executive Summary

Chronic Pain Market 2025

For more details on this report – Request for Sample

Chronic Pain Market Dynamics: Drivers

Advancements in pain management technologies

Technological innovations in healthcare are significantly reshaping the management of chronic pain, utilizing digital health technologies to enhance patient care and improve outcomes. The integration of tools such as wearable devices, mobile applications, virtual reality (VR), and artificial intelligence (AI) is transforming how chronic pain is assessed, monitored, and treated.

These devices track physiological metrics such as heart rate, activity levels, and sleep patterns. They provide real-time feedback to both patients and healthcare providers, enabling better monitoring of pain conditions and facilitating timely interventions. Pain management apps allow patients to log their pain levels, identify triggers, and document responses to treatments. This data is crucial for developing personalized treatment plans tailored to individual patient needs.

Remote patient monitoring enables healthcare providers to collect and analyze patient data outside traditional clinical settings. This is particularly beneficial for chronic pain patients who may face barriers like geographical distance or mobility issues. RPM facilitates timely interventions based on real-time data, leading to improved patient engagement and outcomes.

Furthermore, key players in the industry research activities, initiatives, and launches that would drive this chronic pain market growth. For instance, in November 2024, Pain Relief International, a registered 501(c)(3) non-profit organization recognized as a global leader in sustainable, drug-free pain relief technology, announced a significant initiative aimed at alleviating chronic pain in India. This initiative is particularly crucial given that an estimated 200 million people in the country suffer from ongoing pain, with many rural communities facing substantial barriers to effective pain management solutions.

Chronic Pain Market Dynamics: Restraints

Stringent regulatory environment

The stringent regulatory environment will hinder the growth of the global chronic pain market. The lengthy approval processes mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have a profound impact on the global chronic pain market. While these processes are essential for ensuring the safety and efficacy of new medications and medical devices, they also present several challenges that can hinder market growth.

Regulatory agencies implement stringent standards to ensure that new drugs and medical devices are safe and effective before they reach the market. This comprehensive review process typically involves several stages, including pre-authorization assessments, extensive clinical trials, and thorough documentation. 

The objective is to minimize risks associated with new treatments, particularly for chronic pain conditions where patient safety is critical. However, these rigorous requirements can significantly delay the introduction of potentially beneficial therapies. Thus, the above factors could be limiting the global chronic pain market's potential growth. 

Chronic Pain Market Segment Analysis

The global chronic pain market is segmented based on type, treatment type, distribution channel, and region.

Type:

The neuropathic type segment is expected to hold 50.0% of the global chronic pain market in 2024

The rising incidence of chronic diseases, particularly diabetes and cancer, is driving demand for effective neuropathic pain management solutions. As the population ages, the number of individuals experiencing neuropathic pain is expected to rise significantly. In the U.S., approximately 65% of adults aged 65 and older report suffering from chronic pain, with a substantial portion attributed to neuropathic causes.

Neuropathic pain encompasses a variety of treatment options, including anticonvulsants (such as gabapentin and pregabalin), antidepressants (like amitriptyline), opioids, and topical treatments such as capsaicin patches. These medications target different pathways involved in pain perception and provide relief for many patients.

Furthermore, major players in the industry are focusing more on research activities, innovative launches, and approvals that would drive this segment's growth in the global chronic pain market. For instance, in November 2024, Grünenthal announced that its U.S. subsidiary, Averitas Pharma, Inc., had completed recruitment for the Phase III clinical trial known as AV001. 

This trial is designed to evaluate the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system specifically for treating post-surgical neuropathic pain (PSNP). If the trial results are positive, they could support an extension of QUTENZA's label in the U.S. market.

Chronic Pain Market Geographical Analysis

North America is expected to hold 39.8% of the global chronic pain market in 2024

Chronic pain affects millions of individuals across North America, with conditions such as arthritis, fibromyalgia, neuropathic pain, and cancer-related pain being particularly common. Approximately 50 million adults in the U.S. experience chronic pain, highlighting an urgent need for effective treatment options. This high prevalence drives demand for chronic pain management therapies and significantly contributes to market growth.

According to the Regents of the University of Colorado news in September 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 20% of U.S. adults, over 50 million people, were experiencing chronic pain. Among these individuals, about 7% were classified as having high-impact chronic pain (HICP), which is defined as pain that significantly limits daily activities and functional capabilities.

North America boasts a well-established healthcare infrastructure that facilitates access to a diverse range of pain management therapies. The presence of specialized healthcare systems and pain clinics ensures that patients receive comprehensive care, including innovative treatment options. Innovations in healthcare technology are transforming chronic pain management. The integration of telemedicine, artificial intelligence (AI), and wearable devices allows for improved monitoring and personalized treatment plans. 

Pharmaceutical companies are increasingly focusing on developing alternative therapies, including non-opioid medications and innovative delivery systems. This shift toward safer pain management solutions expands the treatment options available to patients and contributes to chronic pain market growth.

Furthermore, a major number of key players' presence, government initiatives, and launches & approvals would drive this chronic pain market growth. For instance, in April 2025, US Pain is a newly launched initiative in the United States focused on revolutionizing the way chronic pain is managed and treated. Millions of Americans live with chronic pain that lasts for months or even years and often disrupts daily life, work, and emotional well-being. Traditional pain management approaches have often been fragmented, impersonal, or overly reliant on medications, sometimes leaving patients feeling neglected or stigmatized.

Also, in January 2025, JOURNAVX (suzetrigine) is a newly FDA-approved, first-in-class oral, non-opioid pain medication developed by Vertex Pharmaceuticals for adults experiencing moderate-to-severe acute pain. Thus, the above factors are consolidating the region's position as a dominant force in the global chronic pain market.

Asia Pacific is expected to hold 21.4% of the global chronic pain market in 2024

Chronic pain is a leading reason for individuals seeking medical care worldwide. However, in India, a significant portion of the population, especially in rural areas, struggles to access effective analgesic medications and comprehensive pain management solutions. 

Innovations in healthcare technology are significantly transforming chronic pain management throughout the APAC region. The development of advanced pain management devices, telemedicine solutions, and digital health technologies has led to improved monitoring and personalized treatment plans. These advancements not only enhance patient engagement but also increase the effectiveness of managing chronic pain, thereby driving market growth.

Additionally, government initiatives often focus on increasing awareness about chronic pain and its management among both healthcare providers and the general public. By promoting education and training programs, governments can help ensure that patients receive timely and effective treatment for their chronic pain conditions.

For instance, in November 2024, Pain Relief International, a registered 501(c)(3) non-profit organization recognized as a global leader in sustainable, drug-free pain relief technology, announced a significant initiative aimed at alleviating chronic pain in India. This initiative is particularly crucial given that an estimated 200 million people in the country suffer from ongoing pain, with many rural communities facing substantial barriers to effective pain management solutions. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global chronic pain market.

Chronic Pain Market Major Players

The major global players in the chronic pain market include Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc, Bayer AG, Novartis AG, Endo, Inc., Viatris Inc., Eli Lilly and Company., Teva Pharmaceutical Industries Ltd., and Reckitt Benckiser Group PLC, among others.

Chronic Pain Market Key Developments

  • In April 2025, US Pain is a newly launched initiative in the United States focused on revolutionizing the way chronic pain is managed and treated. Millions of Americans live with chronic pain that lasts for months or even years and often disrupts daily life, work, and emotional well-being. Traditional pain management approaches have often been fragmented, impersonal, or overly reliant on medications, sometimes leaving patients feeling neglected or stigmatized.

  • In January 2025, JOURNAVX (suzetrigine) is a newly FDA-approved, first-in-class oral, non-opioid pain medication developed by Vertex Pharmaceuticals for adults experiencing moderate-to-severe acute pain. 

  • In January 2025, KitoTech Medical launched PainPause, an innovative over-the-counter consumer product that offers a safe, drug-free solution for treating pain, including severe and chronic conditions. 

  • In November 2024, the launch of a dedicated operation theatre for pain management at KEM Hospital in Mumbai marks a significant advancement in the treatment of chronic pain conditions. This initiative reflects the growing recognition of pain management as a specialized field within healthcare, focusing on comprehensive strategies to alleviate persistent pain associated with various medical conditions.

  • In September 2024, Nevro Corp. announced the U.S. Food and Drug Administration (FDA) approval and limited market release of its HFX iQ spinal cord stimulation (SCS) system, which features the innovative HFX AdaptivAI technology. This new platform represents a significant advancement in personalized pain management for patients suffering from chronic pain.

  • In September 2024, Hinge Health announced the launch of the Enso 3, a new FDA-cleared wireless device designed to provide effective relief for chronic musculoskeletal pain. This innovative device represents a significant advancement in pain management technology, offering a non-invasive, non-addictive solution that can deliver pain relief within minutes.

  • In July 2024, Stryker launched the MultiGen 2 Radiofrequency Generator in India, a cutting-edge technology designed to enhance the management of chronic joint pain through radiofrequency ablation (RFA). This device provides physicians with greater control and customization during the RFA procedure, which is a minimally invasive technique used to alleviate pain.

Market Scope

Metrics

Details

CAGR

7.5%

Market Size Available for Years

2022-2033

Estimation Forecast Period

2025-2033

Revenue Units

Value (US$ Bn) 

Segments Covered

Type

Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Post-Operative Pain, Migraine, Others

Treatment Type

 Drug Class, Devices

Distribution Channel

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regions Covered

North America, Europe, Asia-Pacific, South America, and the Middle East & Africa

Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Proceed to Buy
  Get Free Sample
  Customize Sample
  Demo Full Report
Chat on WhatsApp
FAQ’s

  • Chronic Pain Market reached US$ 79.96 Billion in 2024 and is expected to reach US$ 142.28 Billion by 2033

  • Key players are Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc, Bayer AG, Novartis AG, Endo, Inc., Viatris Inc., Eli Lilly and Company., Teva Pharmaceutical Industries Ltd., and Reckitt Benckiser Group PLC.
Related Reports
pharmaceuticals iconpharmaceuticals

Peripheral Neuropathy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 October 22

Starting from

$4350

medical-devices iconmedical-devices

Pain Management Devices Market Size, Share, Growth Insights and Forecast 2025-2033

Published: 2025 January 30

Starting from

$5350

medical-devices iconmedical-devices

Wound Care Management Devices Market Size, Share Analysis, Growth Insights and Forecast 2025-2033

Published: 2025 March 06

Starting from

$4350

WhatsApp